Business Wire

Cepton Secures Industry’s Largest ADAS Lidar Series Production Win with Leading Detroit-Based Global Automotive OEM

Share

Lidar solutions provider Cepton Technologies, Inc. (“Cepton”) announced that it has secured an ADAS lidar series production award at a leading, Detroit-based global automotive OEM (“Detroit-based OEM”), which is the industry’s largest award to-date [1]. This represents a landmark milestone both for the lidar industry as well as for Silicon Valley-based Cepton, which celebrates its five-year anniversary this month.

The Detroit-based OEM is expected to deploy Cepton lidars in its next generation of advanced driver assistance systems (ADAS) across multiple vehicle classes and models – not just luxury cars. This marks the potential for an industry-first, mass-market adoption of lidar technology for automotive ADAS, with an anticipated deployment in consumer vehicles starting in 2023.

Cepton secured this path-breaking, series production win in partnership with Koito Manufacturing Co., Ltd. (“Koito”), a leading automotive lighting Tier 1 supplier that is both a Cepton partner and investor. With this partnership, Cepton has provided a non-exclusive license to Koito to manufacture a version of Cepton’s MMT®-based Vista®-X90 automotive grade lidar, using key components and technologies from Cepton. Substantial progress has been made in the Vista®-X90 product development over the past 18 months since the series production award.

The multiple OEM vehicle models already awarded as part of this series production program makes this win the largest in the industry to-date. The deployment of Cepton lidars in those vehicle models, as well as anticipated models to be added in the coming years at the Detroit-based OEM, is expected to significantly exceed that in any of the other publicly announced lidar series production programs. This is a testament to Cepton’s patented MMT® lidars, which utilize a rotation-free, mirrorless and frictionless technology that balances outstanding performance, high reliability and low cost, which are the three key factors integral to delivering mass-market ADAS lidar. Cepton’s MMT® lidars also feature a superior combination of compact size and low power consumption, which maximizes flexibility for vehicle integration, enabling various placement options such as in the fascia, in headlamps, on the roof and behind windshields. Cepton’s Vista®-X90 lidar consequently enables seamless and innovative vehicle-lidar integration.

“We are thrilled to work with an automotive OEM that is not just considered one of the global leaders in the industry but also a recognized pioneer and leader in ADAS and autonomous driving,” said Cepton CEO and co-founder, Dr. Jun Pei. “We are honored to have been chosen to help fulfill their long-term vision for vehicle safety and autonomy. We are also gratified to partner with Koito and leverage their manufacturing and quality leadership in this pathbreaking series production program, which I believe will set the standard for future ADAS lidar adoption.”

Dr. Pei added, “We founded Cepton in 2016 with an emphasis on ADAS and centered our lidar innovation around the goal of making lidar an essential automotive safety sensor in everyday passenger cars. We are now focused on delivering a safer and more enjoyable driving experience to consumers within the next few years.”

About Cepton

Cepton is one of the world’s leading providers of state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smartcities, smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements

Certain statements herein are “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect Cepton’s current expectations or beliefs concerning future events and actual events may differ materially from current expectations. Any such forward-looking statements are subject to various risks and uncertainties, including (i) the success of our strategic relationships, including with our Tier 1 partners and OEM customers, none of which are exclusive; (ii) fluctuations in sales of Cepton’s major customers; (iii) current trends in the automotive markets. Cepton does not undertake to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.

[1] Largest known series production award by number of vehicle models awarded and based on publicly available information

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cepton Media Relations: Faithy Li - media@cepton.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Blackstone and Hudson Pacific Properties Announce Plans for New World-Class Film and TV Studios in the UK2.8.2021 09:00:00 CEST | Press release

Blackstone (NYSE: BX) and Hudson Pacific Properties (NYSE: HPP) plan to create a major new centre for film, TV and digital production in Broxbourne, Hertfordshire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005278/en/ Artist Impression No. 1 (Photo: Business Wire) Funds managed by Blackstone Real Estate Partners and Hudson Pacific Properties acquired a 91-acre site, 17 miles north of central London, through a joint venture for £120 million. The acquisition, with an expected total investment of over £700 million, will be the partners’ first expansion of their Sunset Studios platform outside of the US. The proposed development, which is subject to planning permission, would transform the site into one of the largest world-class film and television studio campuses. The project is expected to create over 4,500 permanent jobs for Broxbourne and the surrounding community and contribute more than £300 million annually int

AMICOGEN Inc. and Lysando AG Bring Partnership to the Next Level With Ownership Participations in Each Other’s Companies2.8.2021 08:00:00 CEST | Press release

South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN. The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando. Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees. The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin®. It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments. „I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, A

Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract2.8.2021 08:00:00 CEST | Press release

Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America. Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospi

Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders2.8.2021 07:00:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210801005028/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation. These molecules have demonstrated potential in many different therapeutic areas.1 Achieving efficient oligonucleotide delivery to target organs and tissues, including the brain, remains a major limitation to their use.1,2 Exicure’s SNAs provide distinct chemical and biochemical properties to oligonucleotides. I

Arqit Releases QuantumCloud™ to Deliver Stronger, Simpler Encryption2.8.2021 06:20:00 CEST | Press release

Arqit Limited (“Arqit”), a leader in quantum encryption technology announces the release of the first version of its service, QuantumCloud™ 1.0. This Platform‑as‑a‑Service software enables customers to secure the communications channels and data of any cloud, edge or end-point device. The service combines transformational and unique advances in both quantum and classical cryptography. The release of QuantumCloud™ 1.0 allows customers to secure devices globally by providing a strong device authentication capability, over which is layered the agreement of symmetric keys between authenticated and authorised devices. Importantly, since there are no asymmetric cryptographic primitives used within the trustless key agreement protocol, the keys can be regarded as safe against future attack using Shor’s algorithm running on a quantum computer. A range of other features will be added in future quarters, culminating in the launch of Arqit’s proprietary quantum satellites, which is targeted for 2

Arqit Registration Statement Related to Business Combination With Centricus Acquisition Corp. Declared Effective By SEC2.8.2021 06:04:00 CEST | Press release

Arqit Limited (“Arqit”), a leader in quantum encryption technology today announced the Registration Statement on Form F-4 in connection with the previously announced business combination (the “Business Combination”) with Centricus Acquisition Corp. (“Centricus”) (Nasdaq: CENHU, CENH, CENHUW), a publicly-listed special purpose acquisition company, has been declared effective by the Securities and Exchange Commission (the “SEC”). Upon closing, the ordinary shares and warrants of Arqit Quantum Inc., a company formed for purposes of completing the Business Combination, will be listed on NASDAQ under the new ticker symbols “ARQQ” and “ARQQW.” The boards of directors of Arqit and Centricus have unanimously approved the Business Combination, and Centricus has set 9:00 a.m. ET on August 31, 2021 as the time and date for an extraordinary general meeting of shareholders to approve the proposals associated with the Business Combination. The proxy statement/prospectus contains important informatio

Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie2.8.2021 01:30:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue Commissioners’ position related to the treatment of a break fee received by Shire plc (“Shire”) in October 2014 from AbbVie Inc. (“AbbVie”). Shire was acquired by Takeda in January 2019. Takeda intends to challenge this outcome through all available legal means including appealing the decision to the Irish courts. On November 28, 2018, Shire received a tax assessment from the Irish Revenue Commissioners for 398 million EUR. This assessment sought to tax a 1,635 million USD break fee Shire received from AbbVie in connection with the terminated offer to acquire Shire made by AbbVie in 2014. Takeda appealed this assessment, and in late 2020 a hearing took place before the Irish Tax Appeals Commission. While Takeda is continuing to assess the substance of the decision, the company will record a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom